Busam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C. (2001). Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. The British Journal of Dermatology, 144(6), 1169–1176.
Article
CAS
PubMed
Google Scholar
Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004). Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology, 22(1), 77–85.
Article
CAS
PubMed
Google Scholar
Baselga, J., Pfister, D., Cooper, M. R., et al. (2000). Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal of Clinical Oncology, 18(4), 904–914.
Article
CAS
PubMed
Google Scholar
Tarceva Package Insert. (2008). OSI pharmaceuticals, Inc and Genentech, Inc.
Google Scholar
Sobrero, A. F., Maurel, J., Fehrenbacher, L., et al. (2008). EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(14), 2311–2319.
Article
CAS
PubMed
Google Scholar
Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., & Shepherd, F. A. (2008). Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada clinical trials group study BR.21. Journal of Clinical Oncology, 26(14), 2350–2357.
Article
CAS
PubMed
Google Scholar
Molinari, E., De Quatrebarbes, J., Andre, T., & Aractingi, S. (2005). Cetuximab-induced acne. Dermatology., 211(4), 330–333.
Article
CAS
PubMed
Google Scholar
Perez-Soler, R., & Saltz, L. (2005). Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? Journal of Clinical Oncology, 23(22), 5235–5246.
Article
PubMed
Google Scholar
Wagner, L. I., & Lacouture, M. E. (2007). Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park), 21(11 Suppl 5), 34–36.
Google Scholar
Perez-Soler, R. (2006). Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clinical Lung Cancer, 8(Suppl 1), S7–S14.
Article
CAS
PubMed
Google Scholar
Perez-Soler, R., & Van Cutsem, E. (2007). Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park), 21(11 Suppl 5), 10–16.
Google Scholar
Racca, P., Fanchini, L., Caliendo, V., et al. (2008). Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: Outcomes from an oncologic/dermatologic cooperation. Clinical Colorectal Cancer, 7(1), 48–54.
Article
CAS
PubMed
Google Scholar
Saltz, L., Kies, M., Abbruzzese, J. L., Azarnia, N., & Needle, M. (2003). The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignanciesPaper presented at: 2003 ASCO Annual Meeting.
Google Scholar
National Cancer Institute NIH, US Department of Health Human Services. (2006). Common terminology criteria for adverse events (CTCAE) version 3.0
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
National Cancer Institute NIH, US Department of Health and Human Services. (2009). Common terminology criteria for adverse events, version 4.0
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
National Cancer Institute NIH, US Department of Health and Human Services. (2017). Common terminology criteria for adverse events (CTCAE) version 5.0
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Lacouture, M. E., Maitland, M. L., Segaert, S., et al. (2010). A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer, 18(4), 509–522.
Article
PubMed
Google Scholar
Lisi, P., Bellini, V., & Bianchi, L. (2014). The epidermal growth factor receptor inhibitor-related skin toxicity index (EGFRISTI): A new tool for grading and managing skin adverse reactions to epidermal growth factor receptor inhibitors. Oncology., 87(5), 311–319.
Article
CAS
PubMed
Google Scholar
De Tursi, M., Zilli, M., Carella, C., et al. (2017). Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: A new tool for more accurate comprehension of quality of life impacts. Oncology Targets of Theraphy, 10, 3007–3015.
Article
Google Scholar
Basch, E., Reeve, B. B., Mitchell, S. A., et al. (2014). Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9), dju244.
Article
PubMed
PubMed Central
Google Scholar
Basch, E., Deal, A. M., Kris, M. G., et al. (2016). Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. Journal of Clinical Oncology, 34(6), 557–565.
Article
CAS
PubMed
Google Scholar
Dueck, A. C., Mendoza, T. R., Mitchell, S. A., et al. (2015). Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncology, 1(8), 1051–1059.
Article
PubMed
PubMed Central
Google Scholar
Bennett, A. V., Dueck, A. C., Mitchell, S. A., et al. (2016). Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Health and Quality of Life Outcomes, 14, 24.
Article
PubMed
PubMed Central
Google Scholar
Arnold, B., Mitchell, S. A., Lent, L., et al. (2016). Linguistic validation of the Spanish version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Support Care Cancer, 24(7), 2843–2851.
Article
PubMed
Google Scholar
Wagner, L. I., Berg, S. R., Gandhi, M., et al. (2013). The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer, 21(4), 1033–1041.
Article
PubMed
Google Scholar
Zubrod, C. G. S. M., Frei, E., Brindley, C., Gold, G. L., Shnider, B., Oviedo, R., Gorman, J., Jones, R., Jonsson, U., Colsky, J., Chalmers, T., Ferguson, B., Dederick, M., Holland, J., Selawry, O., Regelson, W., Lasagna, L., & Owens, A. H. (1960). Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Journal of Chronic Diseases, 11(1), 7–33.
Article
Google Scholar
Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.
Article
CAS
PubMed
Google Scholar
Hays, R. D., Farivar, S. S., & Liu, H. (2005). Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD., 2(1), 63–67.
Article
PubMed
Google Scholar
Oken, M. M., Creech, R. H., Tormey, D. C., et al. (1982). Toxicity and response criteria of the eastern cooperative oncology group. American Journal of Clinical Oncology, 5(6), 649–655.
Article
CAS
PubMed
Google Scholar
Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and Psychological Measurement, 20, 37–46.
Article
Google Scholar
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Erlbaum Associates.
Google Scholar
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.
PubMed
Google Scholar
Reeve, B. B., Wyrwich, K. W., Wu, A. W., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22(8), 1889–1905.
Article
PubMed
Google Scholar
Cronbach, L. (1951). Coefficient alpha and the internal structure of tests. Psychometrika., 16(3), 297–334.
Nunnally, J. (1978). Psychometric theory (2nd ed.). New York: McGaw-Hill Book Company.
Google Scholar
Cohen, J. (1968). Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychological Bulletin, 70(4), 213–220.
Article
CAS
PubMed
Google Scholar
Chren, M. M. (2012). The Skindex instruments to measure the effects of skin disease on quality of life. Dermatologic Clinics, 30(2), 231–236 xiii.
Article
CAS
PubMed
Google Scholar
Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.
Article
CAS
PubMed
Google Scholar